uniQure N.V. $QURE Shares Sold by Monaco Asset Management SAM

Monaco Asset Management SAM lowered its stake in uniQure N.V. (NASDAQ:QURE) by 6.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,000 shares of the biotechnology company’s stock after selling 5,000 shares during the quarter. Monaco Asset Management SAM owned about 0.13% of uniQure worth $976,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. KLP Kapitalforvaltning AS bought a new stake in shares of uniQure during the 2nd quarter worth about $117,000. Teacher Retirement System of Texas acquired a new position in shares of uniQure during the second quarter valued at approximately $151,000. OMERS ADMINISTRATION Corp acquired a new stake in uniQure in the first quarter worth approximately $152,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in uniQure in the second quarter worth approximately $215,000. Finally, XTX Topco Ltd boosted its stake in uniQure by 127.3% during the 1st quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 20,720 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the transaction, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at $27,009,282.84. This trade represents a 25.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Christian Klemt sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the completion of the sale, the chief financial officer owned 217,730 shares of the company’s stock, valued at approximately $11,975,150. This trade represents a 6.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 283,126 shares of company stock worth $11,505,677 over the last ninety days. 4.79% of the stock is currently owned by company insiders.

uniQure Trading Up 1.0%

Shares of QURE opened at $27.79 on Friday. The business’s 50-day moving average price is $42.07 and its 200 day moving average price is $24.23. The stock has a market capitalization of $1.52 billion, a P/E ratio of -7.09 and a beta of 0.59. uniQure N.V. has a 1-year low of $5.50 and a 1-year high of $71.50. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Guggenheim upped their price objective on uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, October 8th. Royal Bank Of Canada cut their price target on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Leerink Partners raised their price objective on shares of uniQure from $48.00 to $68.00 and gave the company an “outperform” rating in a research report on Wednesday, September 24th. Finally, The Goldman Sachs Group dropped their target price on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average price target of $66.75.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.